NICE publishes final draft guidance recommending efanesoctocog alfa as an option for treating and preventing bleeding in ...

Cost and evidence gaps remain barriers to approving funding in the NHS for donanemab and lecanemab. Today we’ve published further draft guidance for public consultation that continues to not recommend ...

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over TA1044 26 February 2025 26 February 2025 Durvalumab with etoposide and either carboplatin or cisplatin for ...

These resources provide access to high quality authoritative evidence and best practice. They are for anyone who works in health and social care and makes decisions about treatments, interventions, or ...

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.

NICE publishes final draft guidance recommending efanesoctocog alfa as an option for treating and preventing bleeding in people aged 2 and over with severe haemophilia A.

All NICE products on oesophageal cancer. Includes any guidance and quality standards.

We need to prioritise areas of guidance development and delivery that will have the greatest impact on the health and care system. To do this we're developing a new centralised approach.

Mental wellbeing is about life satisfaction, optimism, self-esteem, feeling in control, having a purpose and a sense of belonging and support. Older people, including those living in care homes, often ...

All NICE products on people with learning disabilities. Includes any guidance and quality standards.